Results 121 to 130 of about 1,289,326 (214)

A. W. Lynch

open access: yes, 1990
"Dvr. A W Lynch VX 69280 2/107 Aust. General Transport 1942 -1943 - Adelaide River Fenton Airfield".Driver A. W. Lynch VX 69280. 2/107 Australian General Transport 1942 -1943.
Lynch, A. W.
core  

The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review

open access: yesPediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo   +5 more
wiley   +1 more source

Novel variants of unknown significance in the PMS2 gene identified in patients with hereditary colon cancer

open access: yesCancer Management and Research, 2019
Raffaella Liccardo,1 Carlo Della Ragione,2 Nunzio Mitilini,2 Marina De Rosa,1 Paola Izzo,1 Francesca Duraturo11Department of Molecular Medicine and Medical Biotechnologies, School of Medicine, University of Naples “Federico II”, Naples, Italy;
Liccardo R   +5 more
doaj  

Prevalence of MSI‐H/dMMR Colorectal Cancer in Japan: Data From the Clinical Study Group of the University of Osaka‐Colorectal Registry

open access: yesAnnals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1538-1545, September 2026.
Using a multicenter Japanese colorectal cancer cohort from 25 institutions, we analyzed 1464 patients across all disease stages and tumor locations to determine the prevalence and clinicopathological features of MSI‐H/dMMR colorectal cancer. MSI‐H/dMMR tumors accounted for 9.4% of cases overall, were present in 22% of right‐sided colon cancers, and ...
Yoshihiro Morimoto   +27 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez   +17 more
wiley   +1 more source

Les critères diagnostiques du syndrome de Lynch

open access: yes, 2013
Le syndrome de Lynch est décrit depuis longtemps et il est le plus fréquent des syndromes de prédisposition génétique au cancer du côlon, mais il reste très mal connu aujourd’hui.
Janin, Nicolas
core  

Lynch syndrome in the Asian populations

open access: yes, 2016
© 2016 Dr. Chun How GanLynch syndrome is an autosomal dominant genetic disorder. Mutation carriers are at significant risk of developing colorectal and a variety of extra-colonic cancers, often at a younger age compared to sporadic cancers.
Gan, Chun How
core   +1 more source

Synchronous Duodenal and Pancreatic Metastases From Clear Cell Renal Cell Carcinoma 18 Years After Nephrectomy: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT A 63‐year‐old man presented with melena and severe anemia 18 years after nephrectomy for clear cell renal cell carcinoma. Imaging and biopsy confirmed duodenal and pancreatic metastases mimicking pancreaticobiliary malignancy. He underwent pancreaticoduodenectomy.
Ankit Kulkarni   +6 more
wiley   +1 more source

Structured surveillance in Lynch syndrome: effectiveness, limitations, and unmet needs. [PDF]

open access: yesESMO Gastrointest Oncol
Dardenne A   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy